General Announcement::Glenmark launches Tavulus for COPD treatment in Spain becoming one of the first companies to launch

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
11-Oct-2021 12:48:31
Status
New
Announcement Sub Title
Glenmark launches Tavulus for COPD treatment in Spain becoming one of the first companies to launch
Announcement Reference
SG211011OTHR9S3L
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
11/10/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark launches Tavulus for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler

Attachments

SGX_PR_11102021.pdf
Total size =1106K